Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Cabozantinib enters a new Phase 3 trial in combination with atezolizumab
12-05-2018
by DDNews Staff  |  Email the author
EDIT CONNECT

SHARING OPTIONS:

ALAMEDA, Calif. & PARIS—Exelixis and Ipsen announced today the initiation of COSMIC-312, a Phase 3 pivotal trial of cabozantinib (Cabometyx) in combination with atezolizumab (Tecentriq) versus sorafenib in previously untreated advanced hepatocellular carcinoma (HCC). The primary endpoints of the trial are progression-free survival and overall survival. An exploratory arm will also evaluate cabozantinib monotherapy in this first-line setting.
 
“Liver cancer is the fastest-rising cause of cancer-related death in the U.S., underscoring the need for new treatment options for this patient community,” said Gisela Schwab, MD, President, Product Development and Medical Affairs and Chief Medical Officer, Exelixis. “Based on past evidence of potential synergistic effects with cabozantinib and immune checkpoint inhibitors, the combination offers promise for patients with advanced liver cancer who have not received prior treatment.”
 
COSMIC-312 is a multicenter, randomized, controlled Phase 3 pivotal trial that aims to enroll approximately 640 patients at up to 200 sites globally. Patients will be randomized 6:3:1 to one of three arms: cabozantinib (40 mg) and atezolizumab, sorafenib, or cabozantinib (60 mg).
Exelixis is sponsoring COSMIC-312, and Ipsen will co-fund the trial. Ipsen will have access to the results to support potential future regulatory submissions outside of the US and Japan. Genentech, a member of the Roche Group, is providing atezolizumab for use in this trial.
 
“With more than 800,000 new diagnoses of liver cancer worldwide each year and a poor prognosis for patients with advanced disease, there is an urgent need to identify new treatment options,” added R. Kate Kelley, MD, Associate Professor of Clinical Medicine, Division of Hematology/Oncology, University of California, San Francisco, and lead investigator on COSMIC-312. “We look forward to learning whether the combination of cabozantinib and atezolizumab may improve outcomes for previously untreated patients.”
 
Cabometyx tablets are currently approved in the United States for the treatment of patients with advanced RCC. On May 29, 2018, Exelixis announced that the US Food and Drug Administration accepted for filing the supplemental New Drug Application for cabozantinib for previously treated advanced HCC and assigned a Prescription Drug User Fee Act action date of January 14, 2019. In March 2017, the FDA granted orphan drug designation to cabozantinib for the treatment of advanced HCC.
 
Cabozantinib tablets are also approved in the European Union, Norway, Iceland, Australia, Switzerland, South Korea, Canada, Brazil and Taiwan for the treatment of advanced RCC in adults who have received prior VEGF-targeted therapy; in the European Union for previously untreated intermediate- or poor-risk advanced RCC; in Canada for adult patients with advanced RCC who have received prior VEGF targeted therapy; and in the European Union, Norway and Iceland for HCC in adults who have previously been treated with sorafenib.
 
For more information about the COSMIC-312 trial, visit ClinicalTrials.gov.
 
Code: E12051801

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.